Non-small cell lung cancer: Adjuvant and neo-adjuvant chemotherapy
نویسندگان
چکیده
منابع مشابه
Adjuvant chemotherapy for completely resected non-small-cell lung cancer.
PURPOSE To conduct a systematic review and to evaluate the impact of postoperative adjuvant chemotherapy on the survival of patients with completely resected non-small cell lung cancer. METHODS Relevant randomized trials and meta-analyses, published as articles or abstracts, were identified through electronic and hand searches by two reviewers. RESULTS Seven meta-analyses and 26 randomized ...
متن کاملAdjuvant chemotherapy for non-small cell lung cancer.
BACKGROUND Adjuvant chemotherapy (ACT) is known to improve survival in patients with early-stage non-small cell lung cancer. Herein, we describe chemotherapy regimens used, dose modifications, survival, and treatment-related toxicity in the general population. METHODS All cases of non-small cell lung cancer diagnosed in Ontario in the period 2004-2006 who underwent surgical resection (n = 335...
متن کاملAdjuvant chemotherapy for resected non-small cell lung cancer.
Surgery remains the mainstay of therapy for early stage non-small cell lung cancer (NSCLC), but even for stage IA, disease relapse rates remain as high as 30%. Patients with completely resected (R0) N1 disease have about a 50% chance of relapse. In the past 5 years, the benefit of adjuvant chemotherapy has finally been demonstrated for patients with lung cancer. Improvements of 5% to 10% 5-year...
متن کاملAdjuvant Chemotherapy for Resected Non–Small-Cell Lung Cancer
Because of the high rate of distant disease recurrence, the 5-year survival of patients who have undergone complete surgical resection of localized non–small-cell lung cancer (NSCLC) is approximately 50%. Initial results from early studies of adjuvant postoperative chemotherapy reported an adverse effect of alkylating agent and older chemotherapy regimens on survival. Cisplatin-based combinatio...
متن کاملAdjuvant Chemotherapy for Early Stage Non-Small Cell Lung Cancer
Lung cancer is the leading cause of cancer-related mortality in the developed world. Non-small cell lung cancer (NSCLC) represents 85% of cases of lung cancer, and patients have a poor 5-year survival rate. Approximately one third of NSCLC patients present with early-stage disease that is amenable to potentially curative resection and multimodality therapy. Several randomized trials now have co...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Respirology
سال: 2007
ISSN: 1323-7799,1440-1843
DOI: 10.1111/j.1440-1843.2007.01081.x